WHO ICTRP trial
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, CROSS-OVER, ASCENDING SINGLE…
NL-OMON37794 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON37794 |
|---|---|
| Public title | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, CROSS-OVER, ASCENDING SINGLE ORAL DOSE, SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF CB-189,625 IN HEALTHY MALE SUBJECTS. |
| Scientific title | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, CROSS-OVER, ASCENDING SINGLE ORAL DOSE, SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF CB-189,625 IN HEALTHY MALE SUBJECTS. - CB-189,625 SAD study |
| Primary sponsor | Cubist Pharmaceuticals, Inc |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Netherlands |
| Conditions | acute en chronische pijn acute and chronic pain;acute and chronic pain |
| Interventions | Cohort 1: period 1: a single oral dose of 200 mg CB-189,625 or placebo. period 3: a single oral dose of 800 mg CB-189,625 or placebo. period 5: a single oral dose of 1600 mg CB-189,625 or placebo. Cohort 2: period 2: a single oral dose of… |
| Registration date | Jan 16, 2012 |
| Target size | 18 |
| Secondary IDs | 2011-004932-73;NL39026.056.11 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: